IDEAYA Biosciences Reports the First Patient Enrolment in P-I Trial of IDE034

Shots: IDEAYA Biosciences has enrolled the first patient in its P-I dose escalation/expansion trial of IDE034, a B7H3/PTK7 bispecific TOP1 ADC, for solid tumors The company is planning to assess the safety, tolerability, & PK of IDE034 as monotx. in a P-I trial & explore combinations with DDR-targeting agents, incl. its proprietary PARG inhibitor, IDE161…

ByRidhi Rastogi4 days ago

NEWS

Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions

Shots: Biocytogen has entered into an evaluation & option agreement with Merck KGaA to develop antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, incl. antibody-conjugated lipid nanoparticles As per the deal, Biocytogen will provide fully human antibodies from its RenMice platform for evaluation to Merck KGaA’s antibody-conjugated LNP services, with Merck KGaA holding an exclusive…

ByRidhi RastogiSeptember 4, 2025

NEWS

Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors

Shots: Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) tech Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using…

BySenior EditorJanuary 8, 2025

IDEAYA Biosciences Reports the First Patient Enrolment in P-I Trial of IDE034

Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions

Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors

Contact US

FOLLOW US